不同治疗方案对宫颈高危型HPV感染患者的治疗效果分析  

Clinical Effect of Different Treatment Options in Patients with High-Risk HPV Infection

作　　者：朱弘宇[1] 冯祥 罗幼珍[1] Zhu Hongyu;Feng Xiang;Luo Youzhen(Department of Gynaecology,Yichang Central People's Hospital,The First College of Clinical Medical Science,China Three Gorges University,Yichang 443003,China)

机构地区：[1]三峡大学第一临床医学院[宜昌市中心人民医院]妇科,湖北宜昌443003

出　　处：《巴楚医学》2024年第1期50-54,共5页Bachu Medical Journal

基　　金：重大疾病共性机制研究全国重点实验室开放研究课题《铁螯合剂治疗PTEN缺失的子宫内膜癌》。

摘　　要：目的:探讨多种治疗方案对宫颈高危型人乳头瘤病毒(HPV)感染患者的临床治疗效果,为HPV患者的临床治疗提供新思路。方法:采用回顾性研究方法纳入2022年1月—2023年1月在宜昌市中心人民医院治疗的宫颈高危型HPV感染患者501例,根据患者选取的治疗方法分为三组,A组患者给予保妇康栓治疗(n=167),B组患者给予重组人干扰素α-2b凝胶治疗(n=167),C组给予抗HPV生物蛋白敷料治疗(n=167)。比较三组HPV患者治疗有效率、HPV-DNA水平、治疗后HPV阳性率和治疗过程中不良反应发生率,评价临床治疗效果。结果:C组患者治疗总有效率明显高于A组(90.42%vs 74.85%)和B组(90.42%vs 77.25%)(均P<0.05)。三组患者治疗3个月及6个月HPV-DNA水平较治疗前明显下降,且治疗3个月及6个月时,C组患者的HPV-DNA水平较A组和B组明显降低(均P<0.05)。治疗后C组HPV阳性率明显低于A组(6.60%vs 22.75%)和B组(6.60%vs 20.96%)(均P<0.05)。三组患者不良反应发生情况无明显统计学差异(P>0.05)。结论:抗HPV生物蛋白敷料对于宫颈高危型HPV感染患者的治疗效果优于保妇康栓及重组人干扰素α-2b凝胶,且不良反应发生少,值得临床上进一步推广。Objective:To explore the clinical therapeutic effect of multiple treatment methods on patients with high-risk cervical human papillomavirus(HPV)infection,and provide new ideas for clinical treatment of HPV patients.Methods:A total of 501 patients with high-risk cervical HPV infection treated in Yichang Central People's Hospital from January 2022 to January 2023 were included in this retrospective study,and they were divided into three groups according to the treatment methods.Patients in group A were treated with Baofu Kang suppository(n=167),patients in group B were treated with recombinant human interferonα-2b gel(n=167),and group C was treated with anti-HPV bioprotein dressing(n=167).The treatment effective rate,HPV-DNA level,HPV positive rate after treatment and the incidence of adverse reactions during treatment were compared among three groups.Results:The total effective rate in group C was significantly higher than that in group A(90.42%vs 74.85%)and group B(90.42%vs 77.25%)(both P<0.05).The HPV-DNA level in the three groups was significantly decreased at 3 and 6 months after treatment compared with that before treatment,and the HPV-DNA level in the C group was significantly reduced when compared to group A and group B(all P<0.05).After treatment,the HPV positive rate of group C was significantly lower than that of group A(6.60%vs 22.75%)and group B(6.60%vs 20.96%)(both P<0.05).There was no significant difference in the occurrence of adverse reactions among the three groups(P>0.05).Conclusion:The therapeutic effect of anti-HPV biological protein dressing on high-risk cervical HPV infection patients is better than Baofu Kang suppository and recombinant human interferonα-2b gel,which has few adverse reactions and is worthy of further promotion in clinic.

关 键 词：人乳头瘤病毒 高危型人乳头瘤病毒感染 抗人乳头瘤病毒生物蛋白敷料 

分 类 号：R737.33[医药卫生—肿瘤]